Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson’s disease
Objective: to investigate the pattern of substantia nigra - neuromelanin (SN-NM) area loss and contrast ratio (CR) intensity changes in late-stage Parkinson’s disease (LSPD) patients,…High-Pass Filtered Phase MR Imaging to Detect Longitudinal Motor Associations of Iron Accumulation in Parkinson’s Disease
Objective: To assess whether longitudinal changes in deep grey matter nuclei iron content are associated with declining motor function in Parkinson’s disease over a period…Assessing Nigral Functional Connectivity in Parkinson’s Disease with Resting State Functional MRI
Objective: To evaluate functional connectivity of SN with basal ganglia and motor cortex in Parkinson’s disease (PD) using resting state functional MRI (RS fMRI). Background:…Clinical utility of visualization of Nigrosome-1 in patients with Parkinson’s disease
Objective: To determine the inter-rater reliability of Nigrosome-1 detection and its relation to asymmetry of clinical symptoms in Parkinson’s disease (PD). Background: Detection of Nigrosome-1…Volume analysis and localization of midbrain hyperechogenecities via TCS and MRI
Objective: We are presenting follow-up results on our previous study for 3D volumetric measurements of SN hyper-echogenicities, to differentiate PD patients from healthy controls (HC).…Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease
Objective: Non-dopaminergic protein drug targets are of high interest to develop adjuvant treatments for currently insufficiently addressed symptoms of PD. RGS4, a regulator of G-protein…Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease
Objective: To assess the therapeutic potential of chronic vagus nerve stimulation (VNS) to attenuate the behavioral and neuronal deficits observed in Parkinson's disease (PD) by…Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease
Objective: Identify magnetic resonance imaging (MRI) biomarkers of nigrostriatal neurodegeneration in early-stage drug-naïve Parkinson's disease (PD). Background: Diffusion tensor imaging (DTI) is an MRI technique…The study of clinical outcome of deep brain stimulation for the idiopathic Parkinson’s disease at 6 months follow-up
Objective: The aim of this study was to assess the motor and psychiatric outcomes at 6 months after subthalamic nucleus deep brain stimulation (STN-DBS) in…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- Next Page »